Skip to content
Open access

An increase in serum levels of intranuclear proteins is associated with the development of transplant-associated thrombotic microangiopathy.

Nov 2026 · Immunobiology · Vol 231 6, pp. 153264 · 0 citations · 43 references
Medicine

Abstract

Background

Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative therapy for refractory hematologic diseases, but its success is often limited by life-threatening, endothelial injury-related complications such as sinusoidal obstruction syndrome (SOS) and transplant-associated thrombotic microangiopathy (TA-TMA). As early intervention is critical for improving outcomes, the identification of specific predictive biomarkers is urgently needed. Nuclear proteins released from damaged cells, such as high-mobility group box 1 (HMGB1) and histone H3 (H3), are recognized as damage-associated molecular patterns (DAMPs) implicated in endothelial damage and may serve as potential biomarkers. STUDY

Design

We conducted a prospective study, collecting serial blood samples from 115 patients undergoing allogeneic HSCT from pre-conditioning to day 28 post-transplant. Serum levels of HMGB1 and H3 were measured by ELISA, and their association with the development of SOS and TA-TMA was investigated using ROC curve analysis and logistic regression.

Results

During the observation period, 10 patients (8.7%) developed SOS and 13 (11.3%) developed TA-TMA. Notably, an increase in serum HMGB1 from baseline to day 14 or day 28, as well as elevated H3 levels at day 21, were significantly associated with the subsequent development of TA-TMA. Also, HMGB1 levels at day 14 were predictive of the development of SOS. Multivariate analysis confirmed that a high HMGB1 level at day 14 was an independent predictor for TA-TMA.

Conclusion

HMGB1 holds promise as a predictive marker for TA-TMA. However, as this was an exploratory, single-center study with a small sample size, further validation in larger cohorts is required.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.